系统性自身免疫病中的 CAR 类疗法：从深度免疫清除走向持久免疫重置
CAR-based therapies in systemic autoimmunity: from deep immune depletion toward durable immune reset
系统性自身免疫病由自身反应性 B 细胞、分泌抗体的细胞和致病性 T 细胞等构成的网络长期维持，传统免疫抑制和生物制剂常只能压制而不能拆除这一网络，难以实现停药后长期缓解。CAR 类疗法提供了新思路：先深度中断自身反应性免疫环路，再让免疫系统重建。早期临床经验（尤其在难治性系统性红斑狼疮等病中）显示可深度清除 B 细胞、自身抗体快速下降并实现临床缓解。作者提出三层框架——血清学重置、细胞重置和稳态重置，并指出目前只证明了前两层，尚未证明持久稳态重置；同时讨论了长寿命浆细胞、组织清除与外周清除的差别、致病性清除与保护性免疫的权衡等未解问题。
为什么推荐给您：对 CAR 疗法用于自身免疫病这一新兴方向提出机制框架，属重要概念整合但无新数据。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
Systemic autoimmune diseases are sustained by self-renewing networks of autoreactive B cells, antibody-secreting cells, pathogenic T-cell programs and tissue-resident inflammatory niches. Conventional immunosuppression and biologic therapy can reduce disease activity, but often fail to produce durable drug-free remission because the immune architecture that sustains autoreactivity is suppressed rather than dismantled. CAR-based therapies have introduced a different therapeutic concept: deep interruption of autoreactive immune circuits followed by immune reconstitution. Early clinical experience, particularly with CD19-directed CAR-T cells in refractory systemic lupus erythematosus, lupus nephritis, systemic sclerosis and idiopathic inflammatory myopathies, has shown profound B-cell depletion, rapid decline of disease-associated autoantibodies and clinical remission without immediate maintenance immunosuppression in selected patients. These findings support serological reset and provide early evidence for cellular reset, but they do not yet prove durable homeostatic reset. In this Review, we propose a three-tier framework for immune reset after CAR-based therapy: serological reset, cellular reset and homeostatic reset. We use this framework to examine the mechanistic and translational uncertainties now facing the field, including the long-lived plasma-cell kinetic paradox, the distinction between peripheral depletion and tissue eradication, the uncertainty of repertoire-based claims of immune renewal, persistence of autoreactive T-cell memory, the contribution of lymphodepleting conditioning and the trade-off between pathogenic depletion and protective humoral immunity. We argue that future progress will require tissue-validated, clonally resolved and functionally informed definitions of therapeutic success. Longitudinal B-cell and T-cell tracking, paired or protocol-defined tissue analyses, assessment of tertiary lymphoid structures and plasma-cell niches, and formal evaluation of vaccine responsiveness and immune competence are, in our view, important considerations for future studies. The success of CAR-based therapy in systemic autoimmunity should ultimately be judged not by depletion depth alone, but by whether it can rebuild a stable, nonpathogenic and immunologically competent immune system.